



Published in final edited form as:

Curr Immunol Rev. 2019 ; 15(1): 36–40. doi:10.2174/1573395514666180807113928.

T Cells in the Female Reproductive Tract Can Both Block and Facilitate HIV Transmission

Christopher J. Miller^{a,b}, Ronald S. Veazey^{c,d}

^aProfessor of Pathology, Microbiology, and Immunology, Center for Comparative Medicine,

^bCalifornia National Primate Research Center, University of California, Davis, Davis, Ca, 95616

^cProfessor of Pathology and Laboratory Medicine, Tulane University School of Medicine,

^dDivision of Comparative Pathology, Tulane National Primate Research Center, Covington, LA 70433

Abstract

Because HIV is sexually transmitted, there is considerable interest in defining the nature of anti-HIV immunity in the female reproductive tract (FRT) and in developing ways to elicit antiviral immunity in the FRT through vaccination. Although it is assumed that the mucosal immune system of the FRT is of central importance for protection against sexually transmitted diseases, including HIV, this arm of the immune system has only recently been studied. Here we provide a brief review of the role of T cells in the FRT in blocking and facilitating HIV transmission.

Keywords

vagina; cervix; T cell; HIV; sexually transmitted disease

1. INTRODUCTION: The Role of T Cells in Viral Infections, Especially HIV.

Mammals have evolved an elegant immune system to cope with infectious organisms. The adaptive arm of the immune response, consisting of antibodies and T cells, is critical for limiting and clearing viral infections. The humoral immune response consists of antibodies specific for the virus that can capture and neutralize virus particles before they enter the cell and kill virus-infected cells through antibody-dependent cellular cytotoxicity. However, most virus-infected cells can only be cleared by the cellular arm of the adaptive immune system. After infection, the virus uses the protein-synthesis machinery of the host cell to synthesize its own proteins. During this process, some of the newly synthesized viral proteins are degraded into peptide fragments and, if they have sufficient affinity, bind to MHC class I molecules. These MHC class I-peptide complexes will then be presented on the surface of the infected cell. Activated CD8⁺ T cells specific for the viral peptide, recognize the MHC class I-peptide complex and induce apoptosis of the infected cell by releasing cytotoxic granules (1). In contrast, CD4⁺ T cells may be activated by antigens presented by antigen-

presenting cells (APC) or cells expressing MHC class II antigens, yet the mechanisms of these pathways are only now being examined in detail.

Memory T cells provide rapid and highly effective protective immunity against previously encountered pathogens, and can recognize a wide variety of viral antigens. Lymphocytic choriomeningitis virus (LCMV) infection of mice is used as a model to study the role of CD8⁺ and CD4⁺ T cells in both acute and chronic viral infections. When mice, deficient in either CD8⁺ or CD4⁺ T cells, are inoculated with LCMV, they cannot clear the virus and develop persistent infections (2). Thus, in this viral infection of mice, both CD8⁺ and CD4⁺ T cells are required to clear the virus. In humans, both CD8⁺ and CD4⁺ T cells play a central role in protection from diseases caused by measles virus, cytomegalovirus (CMV), hepatitis C virus (HCV), and HIV (3–6). In addition, after human infection with pandemic H1N1 influenza virus, the number of pre-existing CD8⁺ T cells specific for conserved viral epitopes, was associated with disease severity (7). CD8⁺ T cells can also mediate protection from influenza virus challenge. In healthy volunteers challenged with influenza A virus, pre-existing cytotoxic CD4⁺ T cells responding to influenza virus internal proteins were associated with less severe illness and decreased virus shedding (8). Thus, both CD8⁺ and CD4⁺ T cells are important immune effector cells in the protective human immune response against the influenza virus. In general, both CD4⁺ and CD8⁺ T cells are required to successfully combat viral infections likely through antigen-specific, cooperative mechanisms.

In HIV infection, CD4⁺ T-cell responses have been associated with partial protection as virus-specific cytolytic CD4⁺ T cells with unique transcriptional profiles have been shown to predict disease outcome in HIV patients (9). However, less is known regarding the precise role(s) that virus specific CD4⁺ T cells play in control or protection from HIV infection. Cytotoxic CD8⁺ T-cell responses have been examined in the FRT of macaques and humans in a number of studies. In chronic HIV infection, the host does not clear the virus but in most people antiviral cytotoxic T cells blunt virus replication to limit disease severity and delay disease progression. In fact soon after HIV infection, viral replication and HIV RNA levels in plasma decline due to the development of anti-viral T-cell responses (10). Individuals with the highest number of HIV-specific cytotoxic CD8⁺ T cells have lower plasma viral loads than patients with fewer HIV-specific cytotoxic T cells, indicating that cytotoxic CD8⁺ T cells can partially control virus replication (11). The critical role of CD8⁺ T cells was confirmed by studies documenting that loss of CD8⁺ T cells is associated with HIV disease progression (12, 13) and studies showing that HIV escape mutations often occur at HLA-binding sites specific for CD8 epitopes. The strong association of certain HLA-alleles with protection from HIV disease progression, the temporal relationship between viral load decline and increase in HIV-specific CD8⁺ T cells, and the results of CD8⁺ T cell depletion studies in non-human primate (NHP) models, underline the importance of CD8⁺ T cell responses in controlling progression to AIDS (3, 14–16). However, patients who control HIV replication also have an increased number of HIV-specific CD4⁺ T cells, suggesting that cytotoxic anti-HIV CD4⁺ T-cell responses can contribute to slowing the progression of HIV disease (9, 17).

1.2 Anatomic and Phenotypic Distribution of T Cells in the FRT

As detailed in an excellent review (18), until recently, memory T cells were divided into two major subsets: central memory T (TCM) cells and effector memory T (TEM) cells (19). TCM cells express the chemokine receptor CCR7 and the vascular addressing L selectin (CD62L), which enable them to access and enter lymph nodes from blood. TEM cells express little CCR7 and CD62L but have receptors that allow them to access peripheral tissues (for example, the E-selectin ligand Cutaneous Lymphocyte Antigen (CLA) for skin homing (20), $\alpha 4\beta 7$ for gut homing (21) and CCR5 and CD11c for homing to the human FRT (22). Over the past decade, it has become clear that there is a third important subset of memory T cells: tissue-resident memory T cells, or TRM cells (18). TRM cells are found in epithelial barrier tissues at the interface between the host and the environment, such as the gastrointestinal (GI) tract, respiratory tract, reproductive tract and skin (23). TRM cells can respond rapidly to pathogen challenge at these sites prior to recruitment of T cells from the blood. They thus mediate the rapid protective immunity that is the defining feature of adaptive immune memory. The TRM cells in each barrier tissue are enriched for the specific pathogens that have been encountered previously through that barrier epithelium. Thus, the specificity of skin TRM cells is largely different from that of lung TRM cells, and the pathogen specificity of both skin and lung TRM are different from that of gut TRM cells. TRM are identified as CD69+ (24) and/or CD103+ T cells which are abundant in mucosal tissues (25). Finally, TRM cells have a gene expression pattern that is distinct from peripheral blood TEM cells and TCM cells (25), further indicating that they are a unique population of cells.

It is widely believed that primary immune T-cell induction in FRT occurs only in the draining lymph nodes (DLNs) but not in the mucosa itself due to a lack of mucosa-associated lymphoid tissue (MALT) or secondary lymphoid tissues (26, 27). Thus naïve T cells in lymph nodes draining the genital tract are primed by the antigen-bearing dendritic cells (DCs) migrating from the antigen-exposed mucosa and differentiate into memory T cells that are then able to traffic back to mucosal sites through the bloodstream (28–31). However, recent studies suggest that there can be local induction of immunity in the FRT and that local secondary immune responses can protect against viral infection (23, 25, 32). Further, protective vaginal immunity develops in lymph node-deficient mice (33) and lymphoid follicles can form in virus-infected vaginal mucosa (34). It was recently shown that primary induction of CD8+ T-cell responses in the type-II mucosa of the vagina, occurs locally without the help of draining LNs, MALT or any other tissue site of priming (35). Thus primary immune responses to viral infections may be induced in the FRT, and as detailed above, the FRT is rich in antiviral effector TRM T cells.

1.3 Role of FRT CD4+ T Cells in HIV Transmission

Most women acquire HIV through receptive vaginal sex. Exposure to seminal fluid and to various pathogens, including HIV, can cause mucosal inflammation that increases the number of activated CD4+ T cell targets for HIV and promotes local viral replication (36–38). In mice, chlamydia infection has been shown to increase the number of antigen-specific $\alpha 4\beta 7$ + T cells migrating through the female genital tract and into gut-associated lymphoid

tissues (GALT) (39–43). In addition, HIV-infected women express higher levels immune activation markers on T cells in the ectocervix, compared to uninfected women (44). The CD4⁺ T cells recruited to the FRT by inflammatory conditions express the GALT integrin $\alpha 4\beta 7$ and the HIV coreceptor CCR5. In cytobrush samples and blood collected from female sex workers (FSW) in Nairobi, Kenya the integrin $\alpha 4\beta 7$ was expressed on 26.0% of cervical CD4⁺ T cells, and these cells usually expressed the HIV coreceptor CCR5 (45). Th17 cell frequency was higher in the cervix than in blood and cervical IL-17A⁺ CD4⁺ T cells preferentially coexpressed $\alpha 4\beta 7$ and CCR5 (45). Consistent with the hypothesis that these cells are preferential HIV targets, cervical Th17 cells were almost completely depleted in HIV⁺ FSWs compared with HIV⁻ FSWs (45). In addition, studies using single round reporter viruses in NHP models indicate that Th17 cells are the first cells infected in the vagina after SIV or SHIV vaginal challenge (46). Finally, a recent study characterized the phenotype and HIV susceptibility of CD4⁺ T cell in the human endometrium, endocervix and ectocervix of the FRT (47) reporting that CCR5⁺ Th17 cells represent a major T cell subset in the human FRT and that Th17 cells were highly susceptible to HIV-infection. In addition, the susceptibility of CD4⁺ T cells to HIV infection was lowest in the endometrial T cells and highest in ectocervical T cells (47).

Both $\alpha 4\beta 7$ and CCR5 are competent HIV co-receptors for infecting CD4⁺ T cells *in vitro*, however the consistent co-expression of CCR5 and $\alpha 4\beta 7$ on CD4⁺ T cells in the FRT makes it difficult to determine if one or both of these molecules are important co-receptors for virus transmission. Since vaginal SIV transmission can be blunted by systemic infusion of an anti- $\alpha 4\beta 7$ monoclonal antibody (48) or topical vaginal applications of CCR5 fusion inhibitors (49, 50) these molecules must play some role in transmission. As most CCR5⁺ T cells are also $\alpha 4\beta 7$ (45), the results could be due to blocking virion interaction with $\alpha 4\beta 7$ acting as a co-receptor, perturbing $\alpha 4\beta 7$ /CCR5⁺ T-cell physiology or limiting access to target cells. In fact, administration of recombinant rhesus $\alpha 4\beta 7$ antibody results in significant transient decline of $\alpha 4\beta 7$ ⁺ lymphocytes in both the periphery and GI tissues (51). Although the effects of recombinant rhesus $\alpha 4\beta 7$ antibody administration on CCR5⁺ T cells were not reported, it is likely that they were also depleted given the fact that essentially all CCR5⁺ cells are also $\alpha 4\beta 7$ ⁺ (45, 52). In fact, studies in SIV-infected macaques suggest that the rate of $\alpha 4\beta 7$ /CD4⁺ T-cell depletion exceeds that of CCR5⁺ cells, suggesting a greater affinity for, or role for $\alpha 4\beta 7$ in viral pathogenesis (53). However, experimentally blocking of $\alpha 4\beta 7$ with an orally available synthetic anti- $\alpha 4$ small molecule that blocks MAdCAM-1 and binds HIV-gp120 binding *in vitro*, did not protect macaques from SHIV acquisition after vaginal inoculation (54). Thus, the role of $\alpha 4\beta 7$ as an important HIV co-receptor involved in transmission remains difficult to demonstrate experimentally. It may be possible to clarify the role of these co-receptors by characterizing and comparing the founder viruses isolated from individuals with and without genital inflammation. Thus, founder viruses from women with genital tract inflammation would be expected to have HIV founder viruses that preferentially use $\alpha 4\beta 7$ as a co-receptor. Founder viruses from women that acquire HIV despite little inflammation in the FRT would not preferentially use the $\alpha 4\beta 7$ integrin as a co-receptor. However, the vaginal environment is dynamic, and it is difficult to sample women close to the time of actual HIV transmission, so NHP studies are necessary for understanding the earliest events in vaginal HIV transmission (55, 56).

1.4 Role of FRT CD8+ T Cells in Blocking HIV Transmission.

As CD8+ T cells are the dominant lymphocyte in the normal and inflamed FRT, most HIV studies have focused on virus-specific vaginal CD8+ T-cell responses. The first study to document antiviral CTL responses in the FRT, found SIV-specific CTL activity in CD8+ T cells from the vagina of experimentally infected female rhesus macaques (57). SIV p55gag and/or gp160env-specific lysis was detected in cultures of vaginal epithelial, but not submucosal, CD8+ T cells. The estimated SIV-specific precursor CTL frequencies were higher in the vaginal CD8+ intraepithelial lymphocyte population of chronically infected monkeys than in the same cells from acutely infected or naive control monkeys. These results provided the first demonstration that antiviral CTL are present in the vaginal epithelium. Subsequently, Musey et al. (58) demonstrated that HIV-1-specific CTL (involving both CD4 and CD8 cells) could be generated from cervical specimens in HIV-1-infected women. In these HIV-1-infected women, comparisons of intra-individual cervical and blood CTL specificities also indicated that epitopes recognized by CTL in the cervix were commonly recognized in the blood, although relative frequencies of CTL in cervix and blood were not examined (58). In most cases, the frequency of the antiviral CD8+ T cells in the cervicovaginal compartment exceeds the frequency of the antiviral CD8+ T cells in the blood or the draining iliac lymph node. In one study, the percentage of Gag-tetramer-positive CD8+ T cells were as high as 13 to 14% of the CD3+ CD8+ T-cell population in the vaginal and cervix of SIV and SHIV chronically infected macaques (59). Another macaque study confirmed these results, finding that the frequency of SIV Gag tetramer-specific CD8+ T cells was 3-to 30-fold higher in FRT tissues than in peripheral blood of chronically SIV-infected macaques (60). Further, the SIV-specific CD8+ T cells in FRT expressed high levels of CXCR3 and CCR5, chemokine receptors normally expressed on memory T cells that home to inflamed tissues. Thus, in chronic infection the frequency of SIV-specific CD8+ T cells in the FRT is enriched compared with peripheral blood, and these T cells are recruited to the FRT by local inflammation (60).

It has also been demonstrated that there are CD8+ T cell IFN γ responses to HIV-1 CTL peptide epitopes in the cervix of some highly exposed, uninfected Kenyan sex workers. As in chronically infected women, the specificity of these HIV responses was similar to systemic (PBMC) responses. However, HIV-1-specific responses were enhanced in the genital tract compared to the blood, and persisted in some subjects for up to 5 months (61). Although HIV/SIV-specific T cells are present in the FRT of chronically infected women and macaques as described above, they are thought to be largely mono-functional and, thereby, may have limited functional antiviral capacity (62–64).

After vaginal SIV inoculation, robust anti-SIV CTL responses are present in the FRT a few days after the peak plasma vRNA is reached but after the virus has disseminated widely to all lymphoid tissues (65, 66). In contrast, the CD8+ T cell responses are still modest in the draining genital and peripheral lymph nodes at the same time. Thus, after vaginal transmission virus-specific CD8+ T-lymphocyte responses in the FRT are relatively rapid but they cannot prevent virus dissemination (65, 66). However, we found that CD8+ T-cell responses induced by an attenuated lentivirus infection prior to vaginal challenge with pathogenic SIV protect some rhesus macaques from infection and prevented uncontrolled

viral replication and virus dissemination in the majority of animals that became infected (67–69). Further, CD8⁺ T cells in the FRT mediated this protection (68, 69). Thus, immunization with a chimeric simian/human immunodeficiency virus (SHIV) results in a systemic infection that induces a moderate population of SIV-specific CD8⁺ and CD4⁺ T cells with cytolytic potential in the vaginal mucosa (69). Depletion of CD8⁺ T cells at the time of SIV challenge completely abrogates the protection mediated by prior infection with attenuated SHIV. Further, after vaginal SIV challenge, the only significant expansion of SIV-specific T cells occurs in the vagina in these animals, without expansion of T-cell responses in systemic lymphoid tissues (68).

1.5 CONCLUSION

Although the natural CD8⁺ T-cell response to virus infection does not eliminate infection, the fact that some highly exposed, uninfected Kenyan sex workers have cervical anti-HIV CD8⁺ T-cell responses suggests that pre-existing effector T-cell responses in the FRT may be beneficial in resisting HIV transmission. Further, the presence of SIV-specific CD8⁺ T cells in the vagina on the day of vaginal SIV challenge and a modest expansion of local effector T cells is sufficient to prevent uncontrolled SIV replication. It seems that T-cell-based vaccine strategies that can elicit mucosal effector CD8⁺ T-cell populations and avoid inducing systemic T-cell proliferation/activation upon exposure to HIV have the greatest potential for mimicking the success of live-attenuated lentiviral vaccines. On the other hand, the role of cervico-vaginal CD4⁺ T cells, innate responses, the vaginal microbiome and responses to hormonal fluctuations may also play a role in susceptibility or resistance to HIV infection. More studies are still needed to optimally induce effective antibody and cellular responses in the FRT to protect against HIV transmission.

References Cited:

1. Rosendahl Huber S, van Beek J, de Jonge J, Luytjes W, van Baarle D. T cell responses to viral infections - opportunities for Peptide vaccination. *Frontiers in immunology*. 2014;5:171. [PubMed: 24795718]
2. Matloubian M, Concepcion RJ, Ahmed R. CD4⁺ T cells are required to sustain CD8⁺ cytotoxic T-cell responses during chronic viral infection. *J Virol*. 1994;68(12):8056–63. [PubMed: 7966595]
3. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, et al. Control of viremia in simian immunodeficiency virus infection by CD8⁺ lymphocytes. *Science*. 1999;283:857–60. [PubMed: 9933172]
4. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghayeb J, Reimann KA, et al. Memory CD8⁺ T cells are required for protection from persistent hepatitis C virus infection. *J Exp Med*. 2003;197(12):1645–55. [PubMed: 12810686]
5. Snyder CM. Buffered memory: a hypothesis for the maintenance of functional, virus-specific CD8(+) T cells during cytomegalovirus infection. *Immunol Res*. 2011;51(2–3):195–204. [PubMed: 22058020]
6. Griffin DE, Lin WH, Pan CH. Measles virus, immune control, and persistence. *FEMS Microbiol Rev*. 2012;36(3):649–62. [PubMed: 22316382]
7. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. *Nat Med*. 2013;19(10):1305–12. [PubMed: 24056771]

8. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, et al. Preexisting influenza-specific CD4⁺ T cells correlate with disease protection against influenza challenge in humans. *Nat Med*. 2012;18(2):274–80. [PubMed: 22286307]
9. Soghoian DZ, Jessen H, Flanders M, Sierra-Davidson K, Cutler S, Pertel T, et al. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. *Sci Transl Med*. 2012;4(123):123ra25.
10. Pantaleo G, Fauci AS. Immunopathogenesis of HIV infection. *Annu Rev Microbiol*. 1996;50:825–54. [PubMed: 8905100]
11. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. *N Engl J Med*. 1997;337:1267–74. [PubMed: 9345075]
12. Rinaldo C, Huang XL, Fan ZF, Ding M, Beltz L, Logar A, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. *J Virol*. 1995;69:5838–42. [PubMed: 7637030]
13. Klein MR, van Baalen CA, Holwerda AM, Kerkhof Garde SR, Bende RJ, Keet IP, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. *J Exp Med*. 1995;181:1365–72. [PubMed: 7699324]
14. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. *Nat Med*. 1997;3(2):212–7. [PubMed: 9018241]
15. Jin X, Bauer DE, Tuttleton SE, Lewin S, Gettie A, Blanchard J, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. *J Exp Med*. 1999;189:991–8. [PubMed: 10075982]
16. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. *Science*. 2010;330(6010):1551–7. [PubMed: 21051598]
17. Ranasinghe S, Flanders M, Cutler S, Soghoian DZ, Ghebremichael M, Davis I, et al. HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. *J Virol*. 2012;86(1):277–83. [PubMed: 22031937]
18. Park CO, Kupper TS. The emerging role of resident memory T cells in protective immunity and inflammatory disease. *Nat Med*. 2015;21(7):688–97. [PubMed: 26121195]
19. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. *Nature*. 1999;401(6754):708–12. [PubMed: 10537110]
20. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. *Nature*. 1997;389(6654):978–81. [PubMed: 9353122]
21. Berlin C, Berg EL, Briskin MJ, Andrew DP, Kilshaw PJ, Holzmann B, et al. α4β7 Integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. *Cell*. 1993;74:185–95. [PubMed: 7687523]
22. Qualai J, Cantero J, Li LX, Carrascosa JM, Cabre E, Dern O, et al. Adhesion Molecules Associated with Female Genital Tract Infection. *PLoS One*. 2016;11(6):e0156605. [PubMed: 27272720]
23. Jiang X, Clark RA, Liu L, Wagers AJ, Fuhlbrigge RC, Kupper TS. Skin infection generates non-migratory memory CD8⁺ T(RM) cells providing global skin immunity. *Nature*. 2012;483(7388):227–31. [PubMed: 22388819]
24. Wang X, Xu H, Alvarez X, Pahar B, Moroney-Rasmussen T, Lackner AA, et al. Distinct expression patterns of CD69 in mucosal and systemic lymphoid tissues in primary SIV infection of rhesus macaques. *PLoS One*. 2011;6(11):e27207. [PubMed: 22096538]
25. Mackay LK, Stock AT, Ma JZ, Jones CM, Kent SJ, Mueller SN, et al. Long-lived epithelial immunity by tissue-resident memory T (TRM) cells in the absence of persisting local antigen presentation. *Proc Natl Acad Sci U S A*. 2012;109(18):7037–42. [PubMed: 22509047]

26. Iwasaki A Antiviral immune responses in the genital tract: clues for vaccines. *Nat Rev Immunol.* 2010;10(10):699–711. [PubMed: 20829886]
27. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. *Nat Rev Immunol.* 2006;6(2):148–58. [PubMed: 16491139]
28. Lee HK, Zamora M, Linehan MM, Iijima N, Gonzalez D, Haberman A, et al. Differential roles of migratory and resident DCs in T cell priming after mucosal or skin HSV-1 infection. *J Exp Med.* 2009;206(2):359–70. [PubMed: 19153243]
29. Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. *Nature.* 2009;462(7272):510–3. [PubMed: 19898495]
30. Sheridan BS, Lefrancois L. Regional and mucosal memory T cells. *Nat Immunol.* 2011;12(6):485–91. [PubMed: 21739671]
31. Carbone FR. Tissue-Resident Memory T Cells and Fixed Immune Surveillance in Nonlymphoid Organs. *J Immunol.* 2015;195(1):17–22. [PubMed: 26092813]
32. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR. Memory T cells in nonlymphoid tissue that provide enhanced local immunity during infection with herpes simplex virus. *Nat Immunol.* 2009;10(5):524–30. [PubMed: 19305395]
33. Roth KL, Bhavanam S, Jiang H, Gillgrass A, Ho K, Ferreira VH, et al. Delayed but effective induction of mucosal memory immune responses against genital HSV-2 in the absence of secondary lymphoid organs. *Mucosal Immunol.* 2013;6(1):56–68. [PubMed: 22718264]
34. Gillgrass AE, Tang VA, Towarnicki KM, Rosenthal KL, Kaushic C. Protection against genital herpes infection in mice immunized under different hormonal conditions correlates with induction of vagina-associated lymphoid tissue. *J Virol.* 2005;79(5):3117–26. [PubMed: 15709031]
35. Wang Y, Sui Y, Kato S, Hogg AE, Steel JC, Morris JC, et al. Vaginal type-II mucosa is an inductive site for primary CD8(+) T-cell mucosal immunity. *Nat Commun.* 2015;6:6100. [PubMed: 25600442]
36. Bebell LM, Passmore JA, Williamson C, Mlisana K, Iriogbe I, van Loggerenberg F, et al. Relationship between levels of inflammatory cytokines in the genital tract and CD4+ cell counts in women with acute HIV-1 infection. *J Infect Dis.* 2008;198(5):710–4. [PubMed: 18643751]
37. Roberts L, Passmore JA, Mlisana K, Williamson C, Little F, Bebell LM, et al. Genital tract inflammation during early HIV-1 infection predicts higher plasma viral load set point in women. *J Infect Dis.* 2012;205(2):194–203. [PubMed: 22190580]
38. Southern PJ. Missing out on the biology of heterosexual HIV-1 transmission. *Trends Microbiol.* 2013;21(5):245–52. [PubMed: 23489987]
39. Kelly KA, Chan AM, Butch A, Darville T. Two different homing pathways involving integrin beta7 and E-selectin significantly influence trafficking of CD4 cells to the genital tract following Chlamydia muridarum infection. *Am J Reprod Immunol.* 2009;61(6):438–45. [PubMed: 19392981]
40. Kelly KA, Natarajan S, Ruther P, Wisse A, Chang MH, Ault KA. Chlamydia trachomatis infection induces mucosal addressin cell adhesion molecule-1 and vascular cell adhesion molecule-1, providing an immunologic link between the fallopian tube and other mucosal tissues. *J Infect Dis.* 2001;184(7):885–91. [PubMed: 11550128]
41. Kelly KA, Walker JC, Jameel SH, Gray HL, Rank RG. Differential regulation of CD4 lymphocyte recruitment between the upper and lower regions of the genital tract during Chlamydia trachomatis infection. *Infect Immun.* 2000;68(3):1519–28. [PubMed: 10678969]
42. Kelly KA, Wiley D, Wiesmeier E, Briskin M, Butch A, Darville T. The combination of the gastrointestinal integrin (alpha4beta7) and selectin ligand enhances T-Cell migration to the reproductive tract during infection with Chlamydia trachomatis. *Am J Reprod Immunol.* 2009;61(6):446–52. [PubMed: 19392980]
43. Hawkins RA, Rank RG, Kelly KA. Expression of mucosal homing receptor alpha4beta7 is associated with enhanced migration to the Chlamydia-infected murine genital mucosa in vivo. *Infect Immun.* 2000;68(10):5587–94. [PubMed: 10992458]
44. Hirbod T, Kimani J, Tjernlund A, Cheruiyot J, Petrova A, Ball TB, et al. Stable CD4 expression and local immune activation in the ectocervical mucosa of HIV-infected women. *J Immunol.* 2013;191(7):3948–54. [PubMed: 24006463]

45. McKinnon LR, Nyanga B, Chege D, Izulla P, Kimani M, Huibner S, et al. Characterization of a human cervical CD4+ T cell subset coexpressing multiple markers of HIV susceptibility. *J Immunol.* 2011;187(11):6032–42. [PubMed: 22048765]
46. Stieh DJ, Matias E, Xu H, Fought AJ, Blanchard JL, Marx PA, et al. Th17 Cells Are Preferentially Infected Very Early after Vaginal Transmission of SIV in Macaques. *Cell Host Microbe.* 2016;19(4):529–40. [PubMed: 27078070]
47. Rodriguez-Garcia M, Barr FD, Crist SG, Fahey JV, Wira CR. Phenotype and susceptibility to HIV infection of CD4+ Th17 cells in the human female reproductive tract. *Mucosal Immunol.* 2014;7(6):1375–85. [PubMed: 24759207]
48. Byraredddy SN, Kallam B, Arthos J, Cicala C, Nawaz F, Hiatt J, et al. Targeting alpha4beta7 integrin reduces mucosal transmission of simian immunodeficiency virus and protects gut-associated lymphoid tissue from infection. *Nat Med.* 2014;20(12):1397–400. [PubMed: 25419708]
49. Veazey RS, Klasse PJ, Schader SM, Hu Q, Ketas TJ, Lu M, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. *Nature.* 2005;438(7064):99–102. [PubMed: 16258536]
50. Lederman MM, Veazey RS, Offord R, Mosier DE, Dufour J, Mefford M, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. *Science.* 2004;306(5695):485–7. [PubMed: 15486300]
51. Pereira LE, Onlamoon N, Wang X, Wang R, Li J, Reimann KA, et al. Preliminary in vivo efficacy studies of a recombinant rhesus anti-alpha(4)beta(7) monoclonal antibody. *Cell Immunol.* 2009;259(2):165–76. [PubMed: 19616201]
52. Kader M, Wang X, Piatak M, Lifson J, Roederer M, Veazey R, et al. Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. *Mucosal Immunol.* 2009;2(5):439–49. [PubMed: 19571800]
53. Wang X, Xu H, Gill AF, Pahar B, Kempf D, Rasmussen T, et al. Monitoring alpha4beta7 integrin expression on circulating CD4+ T cells as a surrogate marker for tracking intestinal CD4+ T-cell loss in SIV infection. *Mucosal Immunol.* 2009;2(6):518–26. [PubMed: 19710637]
54. Arrode-Bruses G, Goode D, Kleinbeck K, Wilk J, Frank I, Byraredddy S, et al. A Small Molecule, Which Competes with MAdCAM-1, Activates Integrin alpha4beta7 and Fails to Prevent Mucosal Transmission of SHIV-SF162P3. *PLoS Pathog.* 2016;12(6):e1005720. [PubMed: 27348748]
55. Fennessey CM, Keele BF. Using nonhuman primates to model HIV transmission. *Curr Opin HIV AIDS.* 2013;8(4):280–7. [PubMed: 23666391]
56. Veazey RS. Animal models for microbicide safety and efficacy testing. *Curr Opin HIV AIDS.* 2013;8(4):295–303. [PubMed: 23698560]
57. Lohman BL, Miller CJ, McChesney MB. Antiviral cytotoxic T lymphocytes in vaginal mucosa of simian immunodeficiency virus-infected rhesus macaques. *J Immunol.* 1995;155(12):5855–60. [PubMed: 7499875]
58. Musey L, Hu Y, Eckert L, Christensen M, Karchmer T, McElrath MJ. HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women. *J Exp Med.* 1997;185:293–303. [PubMed: 9016878]
59. Stevceva L, Kelsall B, Nacs J, Moniuszko M, Hel Z, Tryniszewska E, et al. Cervicovaginal lamina propria lymphocytes: phenotypic characterization and their importance in cytotoxic T-lymphocyte responses to simian immunodeficiency virus SIVmac251. *J Virol.* 2002;76:9–18. [PubMed: 11739667]
60. Cromwell MA, Carville A, Mansfield K, Klumpp S, Westmoreland SV, Lackner AA, et al. SIV-specific CD8+ T cells are enriched in female genital mucosa of rhesus macaques and express receptors for inflammatory chemokines. *Am J Reprod Immunol.* 2011;65(3):242–7. [PubMed: 21223428]
61. Kaul R, Plummer FA, Kimani J, Dong T, Kiama P, Rostron T, et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. *J Immunol.* 2000;164:1602–11. [PubMed: 10640781]
62. Bere A, Denny L, Naicker P, Burgers WA, Passmore JA. HIV-specific T-cell responses detected in the genital tract of chronically HIV-infected women are largely monofunctional. *Immunology.* 2013;139(3):342–51. [PubMed: 23374084]

63. Gumbi PP, Jaumdally SZ, Salkinder AL, Burgers WA, Mkhize NN, Hanekom W, et al. CD4 T cell depletion at the cervix during HIV infection is associated with accumulation of terminally differentiated T cells. *J Virol.* 2011;85(24):13333–41. [PubMed: 21994461]
64. Olaitan A, Johnson MA, MacLean A, Poulter LW. The distribution of immunocompetent cells in the genital tract of HIV-positive women. *AIDS.* 1996;10(7):759–64. [PubMed: 8805867]
65. Miller CJ, Li Q, Abel K, Kim EY, Ma ZM, Wietgreffe S, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. *J Virol.* 2005;79(14):9217–27. [PubMed: 15994816]
66. Reynolds MR, Rakasz E, Skinner PJ, White C, Abel K, Ma ZM, et al. CD8+ T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little. *J Virol.* 2005;79(14):9228–35. [PubMed: 15994817]
67. Stone M, Ma ZM, Genesca M, Fritts L, Blozis S, McChesney MB, et al. Limited dissemination of pathogenic SIV after vaginal challenge of rhesus monkeys immunized with a live, attenuated lentivirus. *Virology.* 2009;392(2):260–70. [PubMed: 19647847]
68. Genesca M, S PJ, H JJ, Li J, Bost K, Lu D, et al. With minimal systemic T cell expansion, CD8+ T cells mediate protection from vaginal SIV challenge in rhesus macaques immunized with attenuated SHIV89.6. *J Virology.* 2008;82:11181–96. [PubMed: 18787003]
69. Genesca M, McChesney MB, Miller CJ. Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89.6. *J Intern Med.* 2009;265(1):67–77. [PubMed: 19093961]